TCGA-21-1083-01A-01R-0692-07
— · cohortMD1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD1
- subtype
- cohortMD1
- age_years
- 75
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.540
- MYC_TARGETS_V2+0.520
- E2F_TARGETS+0.490
- INTERFERON_ALPHA_RESPONSE+0.430
- G2M_CHECKPOINT+0.410
- MTORC1_SIGNALING+0.290
- OXIDATIVE_PHOSPHORYLATION+0.290
- INTERFERON_GAMMA_RESPONSE+0.280
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.280
- DNA_REPAIR+0.200
Top 10 suppressed
- COAGULATION-0.360
- ANGIOGENESIS-0.290
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.290
- ESTROGEN_RESPONSE_LATE-0.270
- KRAS_SIGNALING_UP-0.270
- APICAL_JUNCTION-0.260
- ESTROGEN_RESPONSE_EARLY-0.250
- UV_RESPONSE_DN-0.250
- PROTEIN_SECRETION-0.230
- HEME_METABOLISM-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-58-A46M-01A-11R-A24H-07 | — | cohortSQ2 | 0.882 |
| 2 | SRR8518168 | — | E | 0.872 |
| 3 | SRR8518219 | — | E | 0.869 |
| 4 | 20020093.Her2HRneg | — | E | 0.853 |
| 5 | SRR8518323 | — | E | 0.852 |
| 6 | 504282dd-4fef-4f70-a709-6a545d00a263 | — | — | 0.852 |
| 7 | SRR2016966 | — | — | 0.850 |
| 8 | TCGA-OL-A6VO-01A-12R-A33J-07 | — | E | 0.848 |
| 9 | TCGA-66-2757-01A-01R-0851-07 | — | cohortMD1 | 0.842 |
| 10 | SRR8613729 | — | E | 0.840 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.540 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.520 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.490 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.430 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.410 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.290 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.290 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.280 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.280 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.140 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.090 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.060 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.050 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.050 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.020 | Inavolisib | — uncovered |